A Four-Arm, Randomized, Crossover, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Doses of CTP-543 on the QT/QTc Intervals in Healthy Volunteers
Latest Information Update: 08 Mar 2022
Price :
$35 *
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Adverse reactions
- Sponsors Concert Pharmaceuticals
- 16 Feb 2022 Status changed from active, no longer recruiting to completed.
- 21 Jan 2022 New trial record